IDEAYA Biosciences Inc
Company Profile
Business description
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Contact
5000 Shoreline Court
Suite 300
South San FranciscoCA94080
USAT: +1 650 443-6209
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
131
Stocks News & Analysis
stocks
Market pricing in further upside in overvalued ASX bank
stocks
Chart of the Week: Lithium is rebounding on rising demand
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,316.60 | 23.80 | -0.25% |
| CAC 40 | 8,398.78 | 30.25 | -0.36% |
| DAX 40 | 25,043.57 | 234.64 | -0.93% |
| Dow JONES (US) | 49,255.18 | 407.48 | -0.82% |
| FTSE 100 | 10,627.04 | 59.14 | -0.55% |
| HKSE | 26,705.94 | 138.82 | 0.52% |
| NASDAQ | 22,611.37 | 142.26 | -0.63% |
| Nikkei 225 | 57,467.83 | 323.99 | 0.57% |
| NZX 50 Index | 13,444.20 | 197.18 | 1.49% |
| S&P 500 | 6,840.66 | 40.65 | -0.59% |
| S&P/ASX 200 | 9,086.20 | 24.30 | -0.27% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |